U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H28F3N3O3
Molecular Weight 463.4935
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAFENOQUINE

SMILES

Cc1cc(nc2c(cc(c(c12)Oc3cccc(c3)C(F)(F)F)OC)NC(C)CCCN)OC

InChI

InChIKey=LBHLFPGPEGDCJG-UHFFFAOYSA-N
InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C24H28F3N3O3
Molecular Weight 463.4935
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tafenoquine is anti-malaria drug originated in Walter reed army institute of research and developed by GSK and 60 Degrees Pharmaceuticals. In 2018 United States Food and Drug Administration (FDA) approved single dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria. Tafenoquine, an 8-aminoquinoline antimalarial, is active against all the stages of Plasmodium species that include the hypnozoite (dormant stage) in the liver. Studies in vitro with the erythrocytic forms of Plasmodium falciparum suggest that tafenoquine may exert its effect by inhibiting hematin polymerization and inducing apoptotic like death of the parasite. In addition to its effect on the parasite, tafenoquine causes red blood cell shrinkage in vitro. Tafenoquine is active against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include P. falciparum and P. vivax. The activity of tafenoquine against the pre-erythrocytic liver stages of the parasite, prevents the development of the erythrocytic forms of the parasite.

CNS Activity

Curator's Comment:: Drug related radioactivity in the brain indicated minimal penetration of the blood brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
217.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ARAKODA

Approved Use

ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older

Launch Date

1.53359994E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
147 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
70 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.5 day
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Other AEs: Headache, Sinus headache...
Other AEs:
Headache (15%)
Sinus headache (15%)
Migraine (15%)
Tension headache (15%)
Dizziness (1%)
Dizziness postural (1%)
Nervous system disorders (22%)
Musculoskeletal and connective tissue disorders (29%)
Back pain (14%)
Gastrointestinal disorders (36%)
Diarrhea (18%)
Nausea (7%)
Vomiting (5%)
Psychiatric disorders (5%)
Abnormal dreams (2%)
Insomnia (2%)
Nightmares (2%)
Sleep disorder (2%)
Somnambulism (2%)
Anxiety disorder (1%)
Panic attack (1%)
Ear and labyrinth disorders (7%)
Motion sickness (5%)
Vertigo (5%)
Vertigo positional (5%)
Stress (1%)
Headache (15%)
Sinus headache (15%)
Migraine (15%)
Tension headache (15%)
Dizziness (1%)
Dizziness postural (1%)
Nervous system disorders (22%)
Musculoskeletal and connective tissue disorders (29%)
Back pain (14%)
Gastrointestinal disorders (36%)
Diarrhea (18%)
Nausea (7%)
Vomiting (5%)
Psychiatric disorders (5%)
Abnormal dreams (2%)
Insomnia (2%)
Nightmares (2%)
Sleep disorder (2%)
Somnambulism (2%)
Anxiety disorder (1%)
Panic attack (1%)
Ear and labyrinth disorders (7%)
Motion sickness (5%)
Vertigo (5%)
Vertigo positional (5%)
Stress (1%)
Sources:
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Other AEs: Headache, Sinus headache...
Other AEs:
Headache (32%)
Sinus headache (32%)
Migraine (32%)
Tension headache (32%)
Dizziness (5%)
Dizziness postural (5%)
Nervous system disorders (35%)
Musculoskeletal and connective tissue disorders (27%)
Back pain (14%)
Gastrointestinal disorders (31%)
Diarrhea (5%)
Nausea (5%)
Vomiting (2%)
ALT increased (4%)
Psychiatric disorders (2%)
Abnormal dreams (1%)
Insomnia (1%)
Nightmares (1%)
Sleep disorder (1%)
Somnambulism (1%)
Depression (1%)
Depressed mood (1%)
Hemolytic anemia (<1%)
Anemia (<1%)
Thrombocytopenia (<1%)
Hyperacusis (<1%)
Meniere's disease (<1%)
Hyperbilirubinemia (<1%)
Jaundice cholestatic (<1%)
Blood bilirubin increased (<1%)
Blood creatinine increased (<1%)
Glomerular filtration rate decreased (<1%)
Amnesia (<1%)
Coordination abnormal (<1%)
Hyperesthesia (<1%)
Hypoesthesia (<1%)
Somnolence (<1%)
Visual field defect (<1%)
Urticaria (<1%)
Headache (32%)
Sinus headache (32%)
Migraine (32%)
Tension headache (32%)
Dizziness (5%)
Dizziness postural (5%)
Nervous system disorders (35%)
Musculoskeletal and connective tissue disorders (27%)
Back pain (14%)
Gastrointestinal disorders (31%)
Diarrhea (5%)
Nausea (5%)
Vomiting (2%)
ALT increased (4%)
Psychiatric disorders (2%)
Abnormal dreams (1%)
Insomnia (1%)
Nightmares (1%)
Sleep disorder (1%)
Somnambulism (1%)
Depression (1%)
Depressed mood (1%)
Hemolytic anemia (<1%)
Anemia (<1%)
Thrombocytopenia (<1%)
Hyperacusis (<1%)
Meniere's disease (<1%)
Hyperbilirubinemia (<1%)
Jaundice cholestatic (<1%)
Blood bilirubin increased (<1%)
Blood creatinine increased (<1%)
Glomerular filtration rate decreased (<1%)
Amnesia (<1%)
Coordination abnormal (<1%)
Hyperesthesia (<1%)
Hypoesthesia (<1%)
Somnolence (<1%)
Visual field defect (<1%)
Urticaria (<1%)
Sources:
400 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 34 years (range: 18-50 years)
n = 62
Health Status: unhealthy
Condition: malaria
Age Group: 34 years (range: 18-50 years)
Sex: M+F
Population Size: 62
Sources:
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Disc. AE: ALT increased, Hemoglobin decreased...
Other AEs: ALT increased, Hemoglobin decreased...
AEs leading to
discontinuation/dose reduction:
ALT increased (0.7%)
Hemoglobin decreased (0.4%)
GFR decreased (0.2%)
Malaria (0.5%)
Pneumonia (0.1%)
Viral infection (0.1%)
Fall (0.1%)
Joint injury (0.1%)
Meniscus lesion (0.1%)
Thermal burn (0.1%)
Soft tissue injury (0.1%)
Upper limb fracture (0.1%)
Upper abdominal pain (0.1%)
Irritable bowel syndrome (0.1%)
Musculoskeletal pain (0.1%)
Depression (0.1%)
Metamorphopsia (0.1%)
Night blindness (0.1%)
Rash (0.1%)
Lactose intolerance (0.1%)
Hyperbilirubinemia (0.1%)
Other AEs:
ALT increased (0.7%)
Hemoglobin decreased (0.4%)
GFR decreased (0.2%)
Malaria (0.5%)
Pneumonia (0.1%)
Viral infection (0.1%)
Fall (0.1%)
Joint injury (0.1%)
Meniscus lesion (0.1%)
Thermal burn (0.1%)
Soft tissue injury (0.1%)
Upper limb fracture (0.1%)
Upper abdominal pain (0.1%)
Irritable bowel syndrome (0.1%)
Musculoskeletal pain (0.1%)
Depression (0.1%)
Metamorphopsia (0.1%)
Night blindness (0.1%)
Rash (0.1%)
Lactose intolerance (0.1%)
Hyperbilirubinemia (0.1%)
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy
n = 36
600 mg 1 times / week multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / week
Route: oral
Route: multiple
Dose: 600 mg, 1 times / week
Sources:
healthy
n = 36
600 mg single, oral
Highest studied dose
healthy
n = 75
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Vomiting (1 patient)
Sources:
600 mg single, oral
Studied dose
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Other AEs: CPK increased, Hemoglobin increased...
Other AEs:
CPK increased (4%)
Hemoglobin increased (2%)
Hypersensitivity (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anxiety disorder 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Anxiety disorder 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Dizziness postural 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Dizziness postural 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Dizziness 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Dizziness 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Panic attack 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Panic attack 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Stress 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Stress 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Migraine 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Migraine 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Sinus headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Sinus headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Tension headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Tension headache 15%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Diarrhea 18%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Diarrhea 18%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Abnormal dreams 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Abnormal dreams 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Insomnia 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Insomnia 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nightmares 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nightmares 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Sleep disorder 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Sleep disorder 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Somnambulism 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Somnambulism 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nervous system disorders 22%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nervous system disorders 22%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Musculoskeletal and connective tissue disorders 29%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Musculoskeletal and connective tissue disorders 29%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Gastrointestinal disorders 36%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Gastrointestinal disorders 36%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Motion sickness 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Motion sickness 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Psychiatric disorders 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Psychiatric disorders 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vertigo positional 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vertigo positional 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vertigo 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vertigo 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vomiting 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Vomiting 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Ear and labyrinth disorders 7%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Ear and labyrinth disorders 7%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nausea 7%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Nausea 7%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
n = 492
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 492
Sources:
Abnormal dreams 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Abnormal dreams 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Depressed mood 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Depressed mood 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Depression 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Depression 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Insomnia 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Insomnia 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nightmares 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nightmares 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Sleep disorder 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Sleep disorder 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Somnambulism 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Somnambulism 1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Psychiatric disorders 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Psychiatric disorders 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Vomiting 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Vomiting 2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Musculoskeletal and connective tissue disorders 27%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Musculoskeletal and connective tissue disorders 27%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Gastrointestinal disorders 31%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Gastrointestinal disorders 31%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Migraine 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Migraine 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Sinus headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Sinus headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Tension headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Tension headache 32%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nervous system disorders 35%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nervous system disorders 35%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
ALT increased 4%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
ALT increased 4%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Diarrhea 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Diarrhea 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Dizziness postural 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Dizziness postural 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Dizziness 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Dizziness 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nausea 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Nausea 5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Amnesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Amnesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Anemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Anemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Blood bilirubin increased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Blood bilirubin increased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Blood creatinine increased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Blood creatinine increased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Coordination abnormal <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Coordination abnormal <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Glomerular filtration rate decreased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Glomerular filtration rate decreased <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hemolytic anemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hemolytic anemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperacusis <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperacusis <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperbilirubinemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperbilirubinemia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperesthesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hyperesthesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hypoesthesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Hypoesthesia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Jaundice cholestatic <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Jaundice cholestatic <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Meniere's disease <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Meniere's disease <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Somnolence <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Somnolence <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Thrombocytopenia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Thrombocytopenia <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Urticaria <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Urticaria <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Visual field defect <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Visual field defect <1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
n = 333
Health Status: unhealthy
Condition: malaria
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Population Size: 333
Sources:
Depression 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Fall 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Hyperbilirubinemia 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Irritable bowel syndrome 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Joint injury 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Lactose intolerance 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Meniscus lesion 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Metamorphopsia 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Musculoskeletal pain 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Night blindness 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Pneumonia 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Rash 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Soft tissue injury 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Thermal burn 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Upper abdominal pain 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Upper limb fracture 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Viral infection 0.1%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Depression 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Fall 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Hyperbilirubinemia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Irritable bowel syndrome 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Joint injury 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Lactose intolerance 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Meniscus lesion 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Metamorphopsia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Musculoskeletal pain 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Night blindness 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Pneumonia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Rash 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Soft tissue injury 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Thermal burn 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Upper abdominal pain 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Upper limb fracture 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Viral infection 0.1%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
GFR decreased 0.2%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
GFR decreased 0.2%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Hemoglobin decreased 0.4%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Hemoglobin decreased 0.4%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Malaria 0.5%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Malaria 0.5%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
ALT increased 0.7%
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
ALT increased 0.7%
Disc. AE
200 mg 1 times / day multiple, oral (starting)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
n = 825
Health Status: unhealthy
Condition: malaria
Age Group: adolescents; adults
Sex: M+F
Population Size: 825
Sources:
Nausea 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Vomiting 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Hemoglobin increased 2%
600 mg single, oral
Studied dose
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Hypersensitivity 2%
600 mg single, oral
Studied dose
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
CPK increased 4%
600 mg single, oral
Studied dose
healthy
n = 52
Health Status: healthy
Sex: unknown
Population Size: 52
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 18 uM]
no [IC50 54 uM]
no [IC50 7.1 uM]
no [IC50 81 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
yes [IC50 0.282 uM]
yes [IC50 0.632 uM]
yes [IC50 1.99 uM]
yes [IC50 15 uM]
yes [IC50 5.61 uM]
yes [Ki 15 uM]
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72.0
yes [Ki 5.2 uM]
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72.0
yes
yes
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72.0
yes
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72.0
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.
1991 Feb
8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.
1993 Oct
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
1995 Nov 24
In-vitro interaction of tafenoquine and chloroquine in Plasmodium falciparum from northwestern Thailand.
2003
Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.
2003
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
2003 Apr
Military aviators, special operations forces, and causal malaria prophylaxis.
2003 Dec
Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis.
2003 Dec 15
Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India.
2003 Jul-Aug
Molecule of the month. Tafenoquine succinate.
2003 May
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.
2003 Nov
New antimalarial drugs.
2003 Nov 10
Malaria chemoprophylaxis: when should we use it and what are the options?
2004 Feb
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
2004 Oct 15
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
2004 Oct 15
Modern malaria chemoprophylaxis.
2005
[Malaria chemoprophylaxis in traveling children].
2005 Jan
Treatment of acute vivax malaria with tafenoquine.
2005 Jan
New strategies for the prevention of malaria in travelers.
2005 Mar
Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
2007 Mar
Tafenoquine: a promising new antimalarial agent.
2007 May
Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.
2008 Aug
How antimalarial drug resistance affects post-treatment prophylaxis.
2008 Jan 11
Glucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian Amazon.
2009
In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays.
2009 Apr 23
A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers.
2009 Aug
Effects of mefloquine and artesunate mefloquine on the emergence, clearance and sex ratio of Plasmodium falciparum gametocytes in malarious children.
2009 Dec 16
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
2009 Jul
Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging.
2009 Nov 18
The role of simple mathematical models in malaria elimination strategy design.
2009 Sep 14
Structural modifications of quinoline-based antimalarial agents: Recent developments.
2010 Apr
Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.
2010 Dec
Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas.
2010 Dec 13
In vitro selection of Plasmodium falciparum drug-resistant parasite lines.
2010 Mar
Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries.
2010 Nov
Operational strategies to achieve and maintain malaria elimination.
2010 Nov 6
Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin.
2010 Oct 29
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.
2013 Dec 17
Patents

Patents

Sample Use Guides

Loading regimen: 200 mg (2 of the 100 mg tablets) once daily for 3 days Maintenance regimen: 200 mg (2 of the 100 mg tablets) once weekly – start 7 days after the last loading regimen dose Terminal prophylaxis regimen: 200 mg (2 of the 100 mg tablets) one-time 7 days after the last maintenance dose
Route of Administration: Oral
After 72 h of tafenoquine exposure, proliferation of L. donovani and Leishmania major promastigotes was inhibited at the micromolar range in a dose-dependent manner, with 50% effective concentrations (EC50s) of 5.6 ± 1.0 uM and 5.3 ± 2.1 uM for L. donovani.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:09:16 UTC 2021
Edited
by admin
on Sat Jun 26 09:09:16 UTC 2021
Record UNII
262P8GS9L9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAFENOQUINE
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
TAFENOQUINE [MI]
Common Name English
SB-252263-AAB
Code English
TAFENOQUINE [WHO-DD]
Common Name English
TAFENOQUINE [INN]
Common Name English
TAFENOQUINE [MART.]
Common Name English
TAFENOQUINE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C271
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
FDA ORPHAN DRUG 385812
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
Code System Code Type Description
MERCK INDEX
M10429
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY Merck Index
CAS
106635-80-7
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
EVMPD
SUB04666MIG
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
NCI_THESAURUS
C73006
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
PUBCHEM
115358
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
MESH
C055852
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
FDA UNII
262P8GS9L9
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
DRUG BANK
DB06608
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
RXCUI
2054023
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
LACTMED
Tafenoquine
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
DRUG CENTRAL
3578
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL298470
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
INN
7835
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
IC50
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC POST-DOSE

Biological Half-life PHARMACOKINETIC